187 related articles for article (PubMed ID: 32421389)
41. Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy.
Boonstra PA; Wind TT; van Kruchten M; Schuuring E; Hospers GAP; van der Wekken AJ; de Groot DJ; Schröder CP; Fehrmann RSN; Reyners AKL
Cancer Metastasis Rev; 2020 Sep; 39(3):999-1013. PubMed ID: 32367253
[TBL] [Abstract][Full Text] [Related]
42. Circulating cell-free tumor DNA analysis in pediatric cancers.
Andersson D; Fagman H; Dalin MG; Ståhlberg A
Mol Aspects Med; 2020 Apr; 72():100819. PubMed ID: 31563277
[TBL] [Abstract][Full Text] [Related]
43. [Clinical Application of Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma--Review].
Chen XF; Wang M; Zhang F; Li JJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Apr; 29(2):638-642. PubMed ID: 33812444
[TBL] [Abstract][Full Text] [Related]
44. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
[TBL] [Abstract][Full Text] [Related]
45. Detection of Circulating Tumor DNA in Plasma: A Potential Biomarker for Esophageal Adenocarcinoma.
Egyud M; Tejani M; Pennathur A; Luketich J; Sridhar P; Yamada E; Ståhlberg A; Filges S; Krzyzanowski P; Jackson J; Kalatskaya I; Jiao W; Nielsen G; Zhou Z; Litle V; Stein L; Godfrey T
Ann Thorac Surg; 2019 Aug; 108(2):343-349. PubMed ID: 31059681
[TBL] [Abstract][Full Text] [Related]
46. [Clinical Application and Research Progress of Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma--Review].
Zhang HY; Yang YL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Dec; 30(6):1917-1921. PubMed ID: 36476926
[TBL] [Abstract][Full Text] [Related]
47. Cell-free tumour DNA testing for early detection of cancer - a potential future tool.
Barbany G; Arthur C; Liedén A; Nordenskjöld M; Rosenquist R; Tesi B; Wallander K; Tham E
J Intern Med; 2019 Aug; 286(2):118-136. PubMed ID: 30861222
[TBL] [Abstract][Full Text] [Related]
48. Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas.
Hickmann AK; Frick M; Hadaschik D; Battke F; Bittl M; Ganslandt O; Biskup S; Döcker D
BMC Cancer; 2019 Mar; 19(1):192. PubMed ID: 30823914
[TBL] [Abstract][Full Text] [Related]
49. Association of Circulating Tumor DNA With Disease-Free Survival in Breast Cancer: A Systematic Review and Meta-analysis.
Cullinane C; Fleming C; O'Leary DP; Hassan F; Kelly L; O'Sullivan MJ; Corrigan MA; Redmond HP
JAMA Netw Open; 2020 Nov; 3(11):e2026921. PubMed ID: 33211112
[TBL] [Abstract][Full Text] [Related]
50. Detection of circulating tumor DNA from non-small cell lung cancer brain metastasis in cerebrospinal fluid samples.
Ma C; Yang X; Xing W; Yu H; Si T; Guo Z
Thorac Cancer; 2020 Mar; 11(3):588-593. PubMed ID: 31944608
[TBL] [Abstract][Full Text] [Related]
51. Circulating Tumor DNA to Monitor Therapy for Aggressive B-Cell Lymphomas.
Kwok M; Wu SP; Mo C; Summers T; Roschewski M
Curr Treat Options Oncol; 2016 Sep; 17(9):47. PubMed ID: 27461036
[TBL] [Abstract][Full Text] [Related]
52. Cell-Free DNA as a Diagnostic Blood-Based Biomarker for Colorectal Cancer: A Systematic Review.
Petit J; Carroll G; Gould T; Pockney P; Dun M; Scott RJ
J Surg Res; 2019 Apr; 236():184-197. PubMed ID: 30694754
[TBL] [Abstract][Full Text] [Related]
53. Circulating free DNA and its potential in the diagnostics and therapy of malignant lymphoma.
Hricko S; Navrkalová V; Janíková A
Klin Onkol; 2023; 37(4):273-280. PubMed ID: 38195381
[TBL] [Abstract][Full Text] [Related]
54. Quantitative Analysis and Monitoring of EZH2 Mutations Using Liquid Biopsy in Follicular Lymphoma.
Nagy Á; Bátai B; Balogh A; Illés S; Mikala G; Nagy N; Kiss L; Kotmayer L; Matolcsy A; Alpár D; Masszi T; Masszi A; Bödör C
Genes (Basel); 2020 Jul; 11(7):. PubMed ID: 32668764
[TBL] [Abstract][Full Text] [Related]
55. Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer.
Watanabe F; Suzuki K; Tamaki S; Abe I; Endo Y; Takayama Y; Ishikawa H; Kakizawa N; Saito M; Futsuhara K; Noda H; Konishi F; Rikiyama T
PLoS One; 2019; 14(12):e0227366. PubMed ID: 31891652
[TBL] [Abstract][Full Text] [Related]
56. Toward liquid biopsies in cancer treatment: application of circulating tumor DNA.
Barlebo Ahlborn L; Østrup O
APMIS; 2019 May; 127(5):329-336. PubMed ID: 30784124
[TBL] [Abstract][Full Text] [Related]
57. Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?
Asante DB; Calapre L; Ziman M; Meniawy TM; Gray ES
Cancer Lett; 2020 Jan; 468():59-71. PubMed ID: 31610267
[TBL] [Abstract][Full Text] [Related]
58. Clinical application of circulating tumor DNA in breast cancer.
Chan JCH; Chow JCH; Ho CHM; Tsui TYM; Cho WC
J Cancer Res Clin Oncol; 2021 May; 147(5):1431-1442. PubMed ID: 33760943
[TBL] [Abstract][Full Text] [Related]
59. ctDNA as a cancer biomarker: A broad overview.
Pessoa LS; Heringer M; Ferrer VP
Crit Rev Oncol Hematol; 2020 Nov; 155():103109. PubMed ID: 33049662
[TBL] [Abstract][Full Text] [Related]
60. Circulating tumor DNA in early-stage breast cancer: new directions and potential clinical applications.
Croessmann S; Park BH
Clin Adv Hematol Oncol; 2021 Mar; 19(3):155-161. PubMed ID: 33739964
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
